Claims
- 1. A method for inhibiting TNF activity, comprising administering to a patient in need thereof an effective amount of a hybrid protein comprising two different coexpressed amino acid sequences forming a heterodimer, each comprising:
(a) at least one amino acid sequence selected from the group consisting of TNF Binding Protein 1 (TBP1), TNF Binding Protein 2 (TBP2), and a fragment of said TBP1 or TBP2 still containing the ligand binding domain; and (b) a subunit of hCG, FSH, LH, TSH, or a fragment of hCG, FSG, LH or TSH which retains the ability of the subunit to form a heterodimer with other subunits thereof; wherein sequences (a) and (b) are joined either directly or through a peptide linker, and in which the sequences (b) in each of said two coexpressed sequences aggregate with each other to dimerize and form a heterodimer.
- 2. The method of claim 1, wherein said two coexpressed amino acid sequences each include the sequence for TBP1 or a fragment thereof having amino acid residues 20-262 or 20-290 of TBP1, as sequence (a) and the respective α and β subunits of hCG or fragments thereof, as sequence (b), and wherein said two coexpressed amino acid sequences form a heterodimer through association of α and β subunits of hCG or fragments thereof.
- 3. The method of claim 1, wherein the patient in need thereof is being treated for Kaposil's sarcoma and metabolic wasting of AIDS.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims the benefit of U.S. Provisional Application no. 60/011,936, filed Feb. 20, 1996.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60011936 |
Feb 1996 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
08804166 |
Feb 1997 |
US |
Child |
09756186 |
Jan 2001 |
US |